Rochester, MN, USA — Resoundant, Inc. is pleased to introduce MRE:connect, an online directory of leading radiology and imaging centers around the U.S. that offer MR Elastography for liver fibrosis staging. MR Elastography is a non-invasive and highly accurate alternative to needle biopsy for staging liver fibrosis assessment.
“MRE:connect was created in response to an increasing number of inquiries, predominantly from the patient community, asking where they can schedule an MRE exam,” said Resoundant Chief Operating Officer, Troy Ziegler. "We felt it was important to help people find this technology."
The number of MRE-ready locations continues to gr...
In current clinical practice, an accurate assessment of hepatic fibrosis is a vital factor for the initiation of Hepatitis C virus (HCV) treatment strategies using direct acting antivirals (DAAs). Typically, patients who are diagnosed with severe fibrosis (>F3) are covered by most payers (both public and private), while patients that exhibit little or no fibrosis are advised to defer DAA treatment and elect for a “watchful waiting” regimen.
However, recent evidence suggests that beginning treatment at a METAVIR score of F2 or lower could help reduce overall DAA costs and improve treatment outcomes, as measured by sustained virologic response (SVR).
Rochester, MN, USA — Resoundant, Inc. is pleased to once again be exhibiting at the International Liver Congress™ (ILC), hosted by the European Association for the Study of the Liver (EASL), being held on April 19 — 23, 2017, at the RAI Exhibition and Convention Centre in Amsterdam, The Netherlands.
"The International Liver Congress™ is an important scientific and clinical meeting," said Richard L. Ehman, MD, CEO of Resoundant, Inc, professor of Radiology and the Blanche R. & Richard J. Erlanger Professor of Medical Research at the Mayo Clinic. “Once again, we are honored to be part of the event.”
Resoundant, Inc. will be exhibiting at Booth #184, where at...